Northwest Biotherapeutics Receives FDA Clearance For Lung Cancer Trial

... Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBT.OB) today announced that ithas received FDA clearance to proceed with Phase I clinical testing of itspersonalized therapeutic cancer vaccine, DCVax(R)-LB, in non-small celllung cancer. The clinical endpoints of the trial will be progression-freesurvival (i.e., delay in progression of the cancer) and overall survival. [click link for full article] ...